Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 287,893 | 322,026 | 351,429 | 279,048 | 239,426 |
| TOTAL | $304,435 | $334,308 | $362,222 | $285,767 | $245,875 |
| Non-Current Assets | |||||
| PPE Net | 3,357 | 3,087 | 2,933 | 2,021 | 1,680 |
| Other Non-Current Assets | 18,455 | 18,911 | 19,281 | 18,993 | 4,995 |
| TOTAL | $21,812 | $21,998 | $22,214 | $21,014 | $6,675 |
| Total Assets | $326,247 | $356,306 | $384,436 | $306,781 | $252,550 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,867 | 4,146 | 4,682 | 3,339 | 2,655 |
| Accrued Expenses | 12,223 | 11,949 | 10,776 | 12,753 | 8,415 |
| TOTAL | $16,701 | $16,095 | $15,458 | $16,547 | $11,525 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 13,704 | 13,951 | 13,994 | 12,811 | 0 |
| TOTAL | $13,704 | $13,951 | $13,994 | $12,811 | $N/A |
| Total Liabilities | $30,405 | $30,046 | $29,452 | $29,358 | $11,525 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 29,959 | 29,663 | 29,584 | 28,536 | 27,543 |
| Common Shares | 3 | 3 | 3 | 2 | 2 |
| Retained earnings | -341,183 | -301,743 | -264,238 | -228,434 | -198,716 |
| TOTAL | $295,842 | $326,260 | $354,984 | $277,423 | $241,025 |
| Total Liabilities And Equity | $326,247 | $356,306 | $384,436 | $306,781 | $252,550 |